Cover Image

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

TO THE EDITOR: In multiple myeloma (MM), measurable residual disease (MRD) is defined as a low-level detection of malignant plasma cells (PCs) that persist after treatment. MM MRD from bone marrow (BM) compartment characterizes the treatment efficacy, is highly predictive for outcome, and was theref...

Full description

Saved in:
Bibliographic Details
Main Authors: Kriegsmann, Katharina (Author) , Manta, Calin-Petru (Author) , Schwab, Ricarda (Author) , Mai, Elias K. (Author) , Raab, Marc-Steffen (Author) , Salwender, Hans J. (Author) , Fenk, Roland (Author) , Besemer, Britta (Author) , Dürig, Jan (Author) , Schroers, Roland (Author) , von Metzler, Ivana (Author) , Hänel, Mathias (Author) , Mann, Christoph (Author) , Asemissen, Anne M. (Author) , Heilmeier, Bernhard (Author) , Bertsch, Uta (Author) , Huhn, Stefanie (Author) , Müller-Tidow, Carsten (Author) , Goldschmidt, Hartmut (Author) , Hundemer, Michael (Author)
Format: Article (Journal)
Language:English
Published: January 27, 2023
In: Blood advances
Year: 2023, Volume: 7, Issue: 3, Pages: 379-383
ISSN:2473-9537
DOI:10.1182/bloodadvances.2022008005
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2022008005
Get full text
Author Notes:Katharina Kriegsmann, Calin Manta, Ricarda Schwab, Elias K. Mai, Marc S. Raab, Hans J. Salwender, Roland Fenk, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M. Asemissen, Bernhard Heilmeier, Uta Bertsch, Stefanie Huhn, Carsten Müller-Tidow, Hartmut Goldschmidt, and Michael Hundemer
Description
Summary:TO THE EDITOR: In multiple myeloma (MM), measurable residual disease (MRD) is defined as a low-level detection of malignant plasma cells (PCs) that persist after treatment. MM MRD from bone marrow (BM) compartment characterizes the treatment efficacy, is highly predictive for outcome, and was therefore introduced as a consensus criterion for response assessment.1,2 While BM aspirate is considered the primary source of sample for MM MRD assessment, this technique is challenging in terms of repeated BM punctures, dilution by peripheral blood (PB), extramedullary disease, and heterogenous MM tumor spread throughout the BM compartment.3 To overcome these obstacles, MM MRD detection in PB samples was established.4,5 Recent studies have demonstrated that circulating malignant PCs can be detected by next-generation flow cytometry (NGF) at first diagnosis (FD) of MM.6 Circulating malignant PC detection by NGF after treatment is challenging, particular due to low frequency of malignant PCs circulating in the PB, and lacks additional studies with a sufficient number of patients.7-9
Item Description:Gesehen am 23.03.2023
Physical Description:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2022008005

Similar Items